Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3147Triple Negative Breast Neoplasms 515Ovarian Neoplasms 230Colorectal Neoplasms 192Carcinoma, Non-Small-Cell Lung 190Prostatic Neoplasms 184Neoplasms 177Lung Neoplasms 165Neoplasm Metastasis 164Melanoma 119Stomach Neoplasms 114Pancreatic Neoplasms 113Endometrial Neoplasms 107Uterine Cervical Neoplasms 95Squamous Cell Carcinoma of Head and Neck 88Head and Neck Neoplasms 82Colonic Neoplasms 82Carcinoma, Intraductal, Noninfiltrating 82Sarcoma 63Breast Carcinoma In Situ 62Carcinoma, Renal Cell 61Urinary Bladder Neoplasms 60Motor Activity 59Esophageal Neoplasms 58Brain Neoplasms 50Lymphedema 44Breast Cancer Female 41Advanced Breast Cancer 40Liver Neoplasms 39HER2-positive Breast Cancer 38

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Overexpression × Breast × 1 year × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡